15 June 2020
https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaa084/5857810
Midkine and chronic kidney disease–associated multisystem organ dysfunctions
This review summarizes the growing body of evidence supporting MK’s potential role in driving CKD-related multisystem disease, including MK’s relationship with the endothelial glycocalyx, the deranged MK levels and glycocalyx profile in CKD patients and a proposed model of MK organ interplay in CKD disease processes and highlights the importance of ongoing research into MK’s potential as a therapeutic target.
Victoria K Campbell, Ryan P Gately, Rathika Krishnasamy, Dominic Burg, Graham R Robertson, Nicholas A Gray
Midkine News 2020, page-31
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 309518 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 379373 | 2 |
View Market Depth
| Last trade - 11.41am 31/07/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable